Background: To identify the optimal interval for repeat prostate-specific antigen (PSA) testing to screen for prostate cancer in healthy adults.
introduction
Prostate cancer is a common cancer in males worldwide [1] ; approximately 400 000 new cases of prostate cancer are diagnosed every year, and prostate cancer comprises 9.2% of all cases of cancer in males [2] . Compared with Western countries, the age-adjusted incidence rate of prostate cancer is low in Japan [2] but is gradually increasing [3] .
Prostate-specific antigen (PSA) is commonly used for screening for prostate cancer. The PSA test is more sensitive than the digital rectal examination to detect prostate cancer [4] . Men whose serum PSA level is >4.0 ng/ml are required to undergo an additional work-up for prostate cancer [4, 5] . Though a previous study showed that prostate cancer screening reduces the rate of death [6] , the net benefits are still modest [7] .
Mixed evidence regarding the benefits and limitations of PSA screening has resulted in different screening recommendations. For example, the National Institute for Health and Clinical Excellence (UK) guidelines [8, 9] and The US Preventive Services Task Force in the United States [10] do not currently recommend screening for prostate cancer. By contrast, the Japan Urological Association (JUA) guidelines strongly recommend screening but do not comment on the optimal screening intervals [8, 9] .
Even among organizations that recommend screening, screening intervals vary widely. The American Cancer Society (ACS) recommends PSA testing in men >50 years and subsequent annual testing for those who have an initial PSA of >2.5 ng/ml or biannual testing for men with an initial PSA <2.5 ng/ml of PSA [11] . The American Urological Association recommends annual PSA testing in individuals over 40 years old [12] irrespective of previous PSA levels.
Thus, we aimed to identify the optimal interval for PSA testing when used to screen for prostate cancer in healthy male adults using a large longitudinal cohort in Japan. 
measurements
Annual health checkups consisted of an initial evaluation during which demographic information and medical history were collected. Serum blood test included PSA measurement. PSA assays were carried out by Lumipulse F (Fujirebio, Tokyo, Japan). Persons with PSA ‡4.0 ng/ml were referred for additional evaluation [4, 7] . Participants were divided on the basis of age (under 50 years old and over 50 years old) in accordance with ACS and JUA guidelines [5, 9] . The screening interval was based on a reported 1% incidence of prostate cancer from a previous study [13] .
statistical methods
The majority of data analysis was performing using SPSS software 15.0J (SPSS Japan, Tokyo, Japan). However, 95% confidence intervals (CI), which were based on an exact binominal [14] , were calculated using Stata version 10 (STATA Corp, College Station, TX).
Responses were analyzed using descriptive statistics, including mean, variance, standard deviation (SD), and percents. The chi-square or Fisher's exact tests were used for cross-tabulated data and t-tests were used to compare means of continuous data. For multivariate logistic regression, potential independent variables with a P-value <0.25 during univariate analysis and known clinical importance were chosen to evaluate adjusted risk factors related to the development of prostate cancer at 3 years, reported as adjusted odds ratios with 95% CI. Respective values for the mean (SD) body mass index (BMI) was 23.7 (2.9) kg/m 2 ; systolic blood pressure (SBP) 123 (16.6) mmHg; hemoglobin A1c at baseline was 5.2% (0.7); low-density lipoprotein (LDL) cholesterol level at baseline were 119.5 (28.7) mg/dl. Other characteristics are shown in Table 1 . The demographic characteristics and laboratory test including PSA level of people between population with 3 years follow-up and those at enrollment were similar.
The mean PSA levels for the entire cohort from 2005 to 2008 increased slightly over the 3-year period (0.015 ng/ml per year). At 3 years, the cumulative incidence of prostate cancer or high PSA ( ‡4.0) was 2.0% (95% CI 1.8-2.5). However, this varied greatly by age and initial level of PSA: at 3 years, for those with PSA <1.0, 1.0-1.9, 2.0-2.9, and 3.0-3.9 ng/ml at baseline, the respective cumulative incidence (95% CI) of prostate cancer or high PSA ( ‡4.0) was 2.0% (95% CI 0.2% to 6.9%), 0.6% (95% CI 0.3% to 1.1%), 3.1% (2.2% to 4.2%), and 20.5% (95% CI 16.4% to 25.1%) in the group over 50 years old and was 0.4% (95% CI 0.1% to 1.1%), 0.4% (95% CI 0.1% to 0.8%), 2.1% (95% CI 1.2% to 3.4%), and 5.0% (95% CI 1.4% to 12.3%) in the group under 50 years old (Figure 1) . At 3 years, 148 patients had high PSA. Of them, 136 were referred for further evaluation; 12 participants were lost to follow-up. Twenty-six participants were diagnosed with prostate cancer (19.1%, 95% CI: 12.9-26.7) and, after thorough investigation, the other 110 participants were not found to have prostate cancer. When participants with high PSA were analyzed according to age, 20 (5.7%) of those of aged >50 years with baseline PSA of 3.0-3.9 ng/dl had prostate cancer at 3 years while no patients aged <50 years had prostate cancer at 3 years. (Tables 2 and 3; Figure 2 ) The incidence of prostate cancer among participants with baseline PSA of 3.0-3.9 ng/dl exceeded 1% at 2 years.
Logistic regression suggested that only age (P < 0.01) and baseline PSA level (P < 0.01) were associated with high PSA or 
discussion
The present study demonstrated that the rate of rise in PSA and the incidence of prostate cancer differ according to age and baseline PSA. Thus, these two variables should be considered when recommending optimal intervals for PSA screening.
Indeed, other investigators have also reported that rate of rise in PSA and the incidence of prostate cancer differ according to baseline PSA [13, 15, 16] , which provides further support to the notion of stratifying PSA screening intervals on the basis of initial PSA levels. Many guidelines and previous studies recommend beginning PSA screening at 50-55 years of age [5, 13, 17] . In our study, only those >50 years developed prostate cancer during the follow-up period, regardless of initial PSA levels. Thus, PSA screening in those under age 50 in this population was associated with a high false-positive ratio. This suggests that it may be appropriate to defer PSA screening until age 50.
In this study, men over 50 years old with initial PSA of 3.0-3.9 ng/ml had a 2-year cumulative incidence of prostate cancer or high PSA of >5%; there were six new prostate cancer patients (1.7%) at 2 years and 20 (5.7%) new prostate cancer patients in the follow-up period. Therefore, a PSA screening interval of every 2 years appears to be most appropriate for Japanese men >50 years with an initial PSA of 3.0-3.9 ng/ml.
There are some limitations to this study. First, a significant proportion of patients did not attend all three yearly checkups. This deficiency could be addressed using other analytic techniques, such as the mixed effect model analysis. However, patients' characteristics including the proportion of high PSA was similar between two groups, suggesting that these two groups may actually be similar. Second, almost all our participants were Japanese, and hence these data likely do not apply to other races. The prevalence of prostate cancer differs among races [18] . For example, African people have a high incidence of prostate cancer compared with Caucasians [18] . Therefore, one guideline recommends earlier screening for African people [5] . By contrast, Asian people, including Japanese men, have a relatively low incidence of prostate cancer [2] . However, with the exception of one small study [19] , there is very little data regarding optimal prostate cancer screening intervals in Asian populations. In our study, there might be some males with higher level of PSA who were missed to detect prostate cancer because not all of those took transrectal ultrasound and biopsy. Moreover, there might be false-negative males with <4.0 of PSA level because they rarely took further examination. However, the probability could be low because those were followed up at Department of Urology or Preventive Medicine annually. Also, considering the relatively slow prognosis of prostate cancer, 3 years might not seem to be so long time in order to evaluate prostate cancer. We need additional researches for further evaluation.
conclusions Males >50 years with PSA of 3.0-3.9 ng/ml at baseline should undergo rescreening at 2 years, whereas for those with PSA <3.0 ng/ml, PSA rescreening at intervals of ‡3 years is more appropriate. PSA screening may not be indicated in males of <50 years of age. disclosure
